US pharmacy benefits manager CVS Health Corp has added new migraine drugs from Teva and Eli Lilly to its list of covered drugs but excluded a rival from Amgen, according to a press report.<
Amgen’s bone-building drug Evenity looks on course for US approval in certain women with osteoporosis after a panel of advisers strongly backed it, but cardiac safety worries mean that it w
Amgen’s osteoporosis bone-forming drug Evenity (romosozumab) has been approved in Japan, ahead of a crunch review by advisers to the US regulator later this month.
A second cut-price biosimilar of Amgen’s Neulasta (pegfilgrastim) long-acting white blood cell booster is to hit the EU market after the European Commission approved Mundipharma’s Pelmeg.
